Cognitive Protective Effect of Newer Antidiabetic Drugs

Summary

The proposed study aims to:

1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria
2. Examine the possible relationship of such effects with the systemic inflammatory and metabolic status in these patients
3. Undertake a network analysis to elucidate the potential pathways linking the observed protective effects, if any, with the observed changes in inflammatory or metabolic parameters

Conditions

• Type 2 Diabetes

Interventions

DRUG

Dapagliflozin

usual and customary doses for type 2 diabetes management

DRUG

Empagliflozin

usual and customary doses for type 2 diabetes management

DRUG

Canagliflozin

usual and customary doses for type 2 diabetes management

DRUG

Sitagliptin

usual and customary doses for type 2 diabetes management

DRUG

Saxagliptin

usual and customary doses for type 2 diabetes management

DRUG

Linagliptin

usual and customary doses for type 2 diabetes management

DRUG

Vildagliptin

usual and customary doses for type 2 diabetes management

Sponsors & Collaborators

• Alexandria University

  lead OTHER

Principal Investigators

• Ahmed F El-Yazbi, PhD · Professor of Pharmacology and Therapeutics, Alexandria University

• Labiba El-Khordagui, PhD · Professor of Pharmaceutics, Alexandria University

• Noha A Hamdy, PhD · Assistant Professor of Clinical Pharmacy, Alexandria University

• Amr El-Feky, MD · Assistant Professor of Internal Medicine, Alexandria University

• Shams T Osman, BPharm · Instructor of Clinical Pharmacy, Alexandria University

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-03-02

Primary Completion

2023-12-31

Completion

2023-12-31

FDA Drug

Yes

Countries

• Egypt

Study Locations